Diversified pharma arm of the Fosun conglomerate, making drugs, vaccines and medical devices, with global investments.
Diversified pharma arm of the Fosun conglomerate, making drugs, vaccines and medical devices, with global investments.
This is the Hong Kong share class of the same group as the Shanghai listing. It combines drug manufacturing, medical devices and hospitals with a pharmaceutical distribution business that earns thin margins on large volume, and holds a large minority stake in Sinopharm. Its parent, the Fosun International investment conglomerate, controls it.
In one line: A diversified Chinese pharma holding company, part of the Fosun conglomerate.
Moat: narrow (scale, distribution). Broad hospital distribution plus Fosun-group capital backing for global licensing/investment deals.
Headquarters: Shanghai, China · Founded: 1994 · Employees: 40,603
Size Shanghai Fosun Pharmaceutical (Group) (2196.HK) is a Hong Kong Health Care company (Pharmaceuticals: Major) with a market value of $7.74B, the 192nd largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$15.11 on 18 Nov 2026.
Performance Over six months the shares fell 15.0%, against +4.4% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 5th lowest of 21 in its peer set.
Growth Revenue grew 9.9% over the last twelve months (peer median +13.9%); the operating margin is 6.2% (peer median 16.4%).
Valuation It trades at 9.0× forward earnings against a peer median of 23.3× (cheapest of 15).
Price implies For today's price to make sense, revenue must grow about 20% a year for seven years (Req g). Recent delivered growth is +6%, so the hurdle is +14 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 5.0 points below its cost of capital (7.1% WACC).
Next results Next results expected around 29 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$47.4B | HK$45.0B | HK$44.4B | HK$45.6B | HK$50.9B |
| Revenue growth | — | +1% | -3% | -11% | — |
| Gross profit | HK$21.9B | HK$22.4B | HK$21.2B | HK$21.7B | HK$24.0B |
| EBITDA | HK$7.29B | HK$6.86B | HK$6.33B | HK$4.52B | HK$6.55B |
| Net income | HK$3.79B | HK$3.66B | HK$3.00B | HK$2.65B | HK$4.35B |
| Free cash flow | HK$353M | HK$277M | -HK$229M | -HK$2.45B | -HK$971M |
| Capital expenditure | HK$5.41B | HK$4.82B | HK$4.78B | HK$5.90B | HK$6.86B |
| Total debt | n/a | HK$40.9B | HK$39.0B | HK$39.2B | HK$34.7B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Shanghai Fosun Pharmaceutical (Group) 2196.HK | $7.74B | -15% | +10% | 6% | 9.0× | 19.9% |
| Sbp 1177.HK | $12.2B | +5% | +15% | 30% | 17.5× | -5.7% |
| Jiangsu Hengrui Pharmaceuticals 1276.HK | $44.9B | -24% | +11% | 27% | 28.1× | 9.1% |
| China Resources Pharmaceutical 3320.HK | $3.60B | -7% | +8% | 4% | 5.8× | -4.9% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 2196.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -11.5% | +2.2% | 5th lowest of 21 |
| 6-month return | -15.0% | +4.4% | 5th lowest of 21 |
| Distance from 52-week high | -35.7% | -11.6% | 6th lowest of 21 |
| Revenue growth (TTM) | +9.9% | +13.9% | 9th lowest of 21 |
| Operating margin | 6.2% | 16.4% | 7th lowest of 20 |
| Forward P/E | 9.0× | 23.3× | cheapest of 15 |
| Growth the price implies (Req g, 7 yrs) | 19.9% | 10.4% | 5th most demanding of 14 |
| Growth delivered (Del g) | +5.8% | +9.4% | 2nd lowest of 14 |
| Hurdle (Req g minus delivered) | +14.0 pp | -0.0 pp | 4th most demanding of 14 |
| ROIC minus cost of capital | -5.0 pp | +1.7 pp | 4th lowest of 19 |
| EV / EBITDA | 14.3× | 22.9× | 4th cheapest of 13 |
| Net debt / EBITDA | 3.7× | -0.3× | 4th most indebted of 13 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Shanghai Fosun Pharmaceutical (Group) 2196.HK | Hong Kong | $7.74B | -15% | +10% | 6% | 9.0× | 19.9% | +5.8% |
| Amneal Pharmaceuticals AMRX | United States | $7.62B | +79% | +9% | 16% | 19.2× | 17.2% | +8.7% |
| Alkermes Public ALKS | United States | $7.87B | +27% | +15% | 5% | n/a | 32.5% | +7.3% |
| ALK-abello A/S ALK-B.CO | Denmark | $7.94B | -8% | +16% | 26% | 34.8× | 7.3% | +12.6% |
| Glenmark Pharmaceuticals GLENMARK.NS | India | $7.98B | +10% | 0% | 17% | 33.1× | 27.3% | +9.4% |
| Grifols GRF.MC | Spain | $7.48B | +19% | +1% | 16% | 13.1× | 7.1% | +7.1% |
| Kiniksa Pharmaceuticals International KNSA | United States | $7.47B | +75% | +58% | 14% | 56.6× | 10.4% | +45.5% |
| Corcept Therapeutics CORT | United States | $7.42B | +15% | +30% | 12% | 15.3× | 23.9% | +16.6% |
| ONO Pharmaceutical 4528.T | Japan | $7.33B | -2% | -2% | 22% | 15.3× | -6.8% | +10.8% |
| Shanghai Pharmaceuticals 601607.SS | China | $8.23B | 0% | +4% | 3% | 11.2× | -10.1% | +8.1% |
| Rhythm Pharmaceuticals RYTM | United States | $8.25B | +31% | +61% | -67% | n/a | n/a | n/a |
| Asymchem Laboratories (Tianjin) 002821.SZ | China | $7.27B | +20% | +18% | 17% | 37.4× | n/a | n/a |
| Protagonist Therapeutics PTGX | United States | $8.30B | +26% | +164% | 59% | 1,532.5× | 17.5% | +10.0% |
| Cytokinetics CYTK | United States | $7.15B | -35% | +30% | -625% | n/a | n/a | n/a |
| ImmunityBio IBRX | United States | $7.13B | -17% | +121% | -150% | n/a | n/a | n/a |
| Kyowa Kirin 4151.T | Japan | $8.43B | +9% | +10% | 24% | 16.4× | -4.7% | +9.3% |
| Bachem BANB.SW | Switzerland | $7.06B | 0% | +5% | 19% | 32.4× | n/a | n/a |
| Praxis Precision Medicines PRAX | United States | $8.53B | -9% | -100% | n/a | n/a | n/a | n/a |
| Akeso 9926.HK | Hong Kong | $7.01B | -48% | +42% | -25% | n/a | n/a | n/a |
| Huadong Medicine 000963.SZ | China | $6.69B | -18% | +2% | 9% | 12.5× | -3.9% | +5.3% |
| Alkem Laboratories ALKEM.NS | India | $6.69B | -5% | +13% | 17% | 27.3× | 25.0% | +10.7% |